The verdict
Our read at a glance.
Whether trevogrumab/REGN1033 can preserve lean mass or improve body-composition quality during obesity treatment in a way that translates into clinically meaningful function, durability, and acceptable safety.
- The signal
- The direct public record is sparse: phase 1/2 REGN1033 and trevogrumab registry records, EU Clinical Trials Register sarcopenia results, identity records, peer-reviewed phase 1 GDF8/activin A blockade data, and preclinical REGN1033 rationale. COURAGE obesity-adjunct results should be treated as sponsor-released context until peer-reviewed or registry-posted outcomes are available.
- The unknown
- Whether lean-mass, fat-mass, DXA/MRI, or target-engagement changes translate into strength, mobility, durability, quality of life, or other clinical outcomes, and whether the safety tradeoff remains acceptable in broader populations.
- Our read
- Early signal, high uncertainty. Trevogrumab belongs on the safety/regulatory watch because the evidence is interesting but still far from proving an established obesity or muscle-preservation role.
The explainer
Watch the 15:05 explainer.
5.1K views · May 2026
The mechanism
How it works.
Trevogrumab is an investigational monoclonal antibody that binds and neutralizes myostatin (GDF8), a circulating protein that normally signals muscle to limit its own growth. By soaking up myostatin before it can reach its receptor, the antibody releases that brake, and the hypothesis being tested is that this preserves or builds lean muscle while people lose weight on incretin drugs. Whether removing the brake actually translates into more strength and function, rather than just more lean mass on a scan, is still an open question in early human trials.
Safety & regulatory boundary
The consequential part.
Trevogrumab/REGN1033 is an investigational monoclonal antibody, not an approved wellness or obesity product and not a peptide-market item. It should not be treated as interchangeable with bimagrumab, follistatin claims, SARMs, supplements, research-use products, or internet-market anti-myostatin products.
What's next
What we're watching.
Peer-reviewed or registry-posted COURAGE outcomes, endpoint-specific functional data, adverse-event and immunogenicity reporting, durability after treatment, and whether phase 2 body-composition signals become regulator-reviewable clinical outcomes.
Context
Why this is discussed.
As incretin drugs move weight downward, preserving strength and function has become a major unanswered clinical and commercial question. Trevogrumab sits at the boundary between a plausible muscle-preservation hypothesis and the harder requirement for outcome-level proof.
The evidence base
18 cited references.
Regulatory & labels2
EU Clinical Trials Register / Regeneron Pharmaceuticals · EudraCT 2013-003134-33; results published 2018-05-01
U.S. Food and Drug Administration · Current page checked 2026-05-16
Registered trials8
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT01507402; completed; last posted 2012-11-14
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT01720576; completed; last posted 2013-09-12
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT01910220; completed; last posted 2014-11-10
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT01963598; completed; last posted 2016-03-28
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT02741739; completed; last posted 2016-10-14
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT02943239; completed; last posted 2024-08-09
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT03710941; withdrawn; last posted 2019-04-29
ClinicalTrials.gov / Regeneron Pharmaceuticals · NCT06299098; active not recruiting; last posted 2026-05-08
Peer-reviewed journals3
Gonzalez Trotter, Donahue, Wynne et al. · 2025-05-13
Mastaitis, Gomez, Raya et al. · 2025-05-13
Journal of Cachexia, Sarcopenia and Muscle · 2016
Indexed literature (PubMed)3
Latres et al. · 2015
Salzler et al. · 2016
Review authors · 2014
Sponsor & other sources2
NCATS · Current page checked 2026-05-16
IUPHAR/BPS Guide to Pharmacology · Current page checked 2026-05-16
Keep reading